MARKET

ADVM

ADVM

Adverum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.90
-0.69
-4.43%
Closed 17:49 08/12 EDT
OPEN
14.93
PREV CLOSE
15.59
HIGH
15.97
LOW
13.36
VOLUME
2.17M
TURNOVER
--
52 WEEK HIGH
26.98
52 WEEK LOW
4.960
MARKET CAP
1.20B
P/E (TTM)
-12.2644
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADVM stock price target is 27.38 with a high estimate of 36.00 and a low estimate of 20.00.

EPS

ADVM News

More
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 21h ago
Adverum Biotechnologies Announces A $200M Common Stock offering
Benzinga · 1d ago
Adverum Biotechnologies shares are trading lower after the company announced a $200 million public common stock offering.
Benzinga · 1d ago
Adverum Biotechnologies Announces $200M Public Offering Of Common Stock
REDWOOD CITY, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that
Benzinga · 1d ago
Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -20.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2d ago
Adverum Biotechnologies shares are trading higher after the company announced "positive" interim data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal inject gene therapy.
Benzinga · 2d ago
Adverum Biotechnologies Q2 EPS $(0.36) Misses $(0.28) Estimate
Adverum Biotechnologies (NASDAQ:ADVM) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 56.52 percent decrease over losses of $(0.23) per
Benzinga · 2d ago
Adverum Biotechnologies Announces Interim Data From Cohorts 1-4 From OPTIC Phase 1 Trial Of ADVM-022 Intravitreal Gene Therapy For wet AMD
REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today
Benzinga · 2d ago

Industry

Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
+1.79%

Hot Stocks

Symbol
Price
%Change

About ADVM

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.
More

Webull offers kinds of Adverum Biotechnologies Inc stock information, including NASDAQ:ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.